Connetics' Extina hits new endpoint in Phase III

Working to overcome a 2004 FDA rejection, researchers at Connetics say that Extina--an experimental therapy for seborrheic dermatitis--proved effective in a new Phase III trial. Regulators had rejected the therapy two years ago after a pivotal trial failed to show its superiority to a placebo. After the latest four-week trial involving 1,162 patients, though, 56 percent of volunteers reported an improvement in symptoms compared to 42 percent who received a placebo.

- read the report on Extina from the StreetInsider

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.